Monyan Pharmaceutical Secures RMB 100 Million Series B Funding Led by Langzi Han-Asia to Advance Oncology Supportive Care Pipeline

VCBeat has learned that Hubei Monyan Pharmaceutical Co., Ltd. (“Monyan”) recently completed a Series B financing round worth hundreds of millions of yuan. The round was led by Beijing Langzi Hanya Asset Management Co., Ltd., with participation from Jinggangshan Zhendong Shenghong Investment Co., Ltd., Yangzhou Jiaxian Venture Capital Partnership (Limited Partnership), and existing shareholders. This financing will support Monyan’s rapid development, strengthen its product portfolio, and expand its R&D pipeline.

MONYAN is a modern high-tech pharmaceutical company dedicated to the mission of “improving the quality of life for cancer patients” and focused on addressing “cancer treatment-related conditions.” Since its establishment, the company has been committed to exploring the treasures of traditional Chinese medicine, developing classic prescriptions from renowned senior TCM practitioners and active ingredients derived from natural medicines into drugs that meet clinical needs. The company’s team consists of seasoned technical experts from the industry, boasting extensive experience and leading technological advantages in the pharmaceutical field. Its flagship product, “Shengbai Oral Liquid,” is a formulation based on a classic prescription from a renowned senior TCM practitioner, used to treat leukopenia induced by radiotherapy and chemotherapy. Its efficacy can be evaluated using quantitative indicators. It has been included in the Chinese Pharmacopoeia, listed in multiple clinical application guidelines and expert consensus statements, and granted an international PCT patent. MONYAN has now initiated its global expansion strategy for traditional Chinese medicine, formally partnering with Sutter Health in Southern California, USA, and commencing the hospital’s access approval process. Currently, the company has multiple projects under development, with a R&D pipeline covering cancer treatment-related conditions such as prevention of chemotherapy-induced cardiotoxicity, cancer-related fatigue, drug-induced liver injury, treatment of opioid-induced constipation in advanced-stage cancer, and thrombocytopenia.

The proceeds from this financing will be primarily used to advance the Phase II clinical trials of DH001, a novel Class 1 drug and the world’s first oral cardioprotective agent for preventing doxorubicin-induced cardiotoxicity, as well as to support studies on new indications for marketed products and the expansion of the company’s product pipeline.

Doxorubicin has been a milestone in the history of cancer therapy and is widely used in clinical practice; however, its severe cardiotoxicity has long troubled clinicians and patients. DH001 is an active monomer derived from botanical drugs that can prevent and reduce the incidence and severity of doxorubicin-induced cardiotoxicity by enhancing cardiomyocyte viability, making it suitable for cancer patients undergoing doxorubicin treatment.

DH001 administered to the first subject in Phase II clinical trials in September 2023. The Phase II clinical study of this project is designed to preliminarily evaluate the efficacy of different doses of DH001 in mitigating doxorubicin-induced cardiotoxicity in cancer patients, thereby providing a basis for subsequent confirmatory studies. This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial. The clinical trial will be conducted at 12 clinical centers, including the Harbin Institute of Hematology and Oncology, Peking University Cancer Hospital, Peking University Third Hospital, and the First Affiliated Hospital of Zhengzhou University. Professor Ma Jun, Director of the Harbin Institute of Hematology and Oncology, and Professor Zhu Jun from Peking University Cancer Hospital jointly serve as the principal investigators for the DH001 Phase II clinical trial.

Zhang Min, Chairman of MONYAN, stated:The trend toward treating cancer as a chronic disease is becoming increasingly evident, with “living with cancer” emerging as the new norm. The various toxic side effects of anti-tumor drugs pose significant potential risks to patients’ lives and severely impair their quality of life. The company has been deeply committed to the field of “cancer treatment-related conditions,” continuously expanding its R&D pipeline. In late 2021, it secured Series A financing from Jifan Capital. DH001 demonstrated excellent safety and tolerability profiles in Phase I clinical trials, along with high oral bioavailability, and its Phase II clinical study is currently progressing smoothly.

We sincerely thank all investors for their attention and support of MONYAN. I believe that the joint investment in our Series B financing round by Beijing Langzi Hanya Asset Management Co., Ltd, Jinggangshan Zhendong Shenghong Investment Co., Ltd, Yangzhou Jiaxian Venture Capital Partnership (Limited Partnership), and existing shareholders will significantly accelerate the clinical trials and market launch of DH001. We look forward to seeing DH001 demonstrate strong efficacy in subsequent clinical studies, thereby benefiting a broad population of cancer patients as soon as possible.

Lead investor Langzi Hanya stated: Beijing Langzi Hanya Asset Management Co., Ltd. is the first China-South Korea-Japan joint venture asset management institution in China, with cumulative assets under management reaching RMB 48.8 billion. Life and health have always been a key focus area for the company’s equity investment business. This investment in MONYAN to establish a presence in the oncology-related disease treatment sector reflects not only our confidence in MONYAN’s forward-looking technologies, pipeline, and product portfolio centered on “oncology-related therapeutic areas,” but also our recognition of its core team and commercialization capabilities. With clear positioning and a well-defined strategic track, MONYAN inherits the essence of traditional Chinese medicine classic formulas while upholding integrity and pursuing innovation. We sincerely look forward to MONYAN maintaining its rapid growth momentum and emerging as a leading enterprise in the field of “oncology-related diseases.”